These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30531837)

  • 1. Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis.
    Kessler BE; Mishall KM; Kellett MD; Clark EG; Pugazhenthi U; Pozdeyev N; Kim J; Tan AC; Schweppe RE
    Oncogene; 2019 Apr; 38(14):2565-2579. PubMed ID: 30531837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.
    Beadnell TC; Mishall KM; Zhou Q; Riffert SM; Wuensch KE; Kessler BE; Corpuz ML; Jing X; Kim J; Wang G; Tan AC; Schweppe RE
    Mol Cancer Ther; 2016 Aug; 15(8):1952-63. PubMed ID: 27222538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p63 drives invasion in keratinocytes expressing HPV16 E6/E7 genes through regulation of Src-FAK signalling.
    Srivastava K; Pickard A; McDade S; McCance DJ
    Oncotarget; 2017 Mar; 8(10):16202-16219. PubMed ID: 26001294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGFβ induces epithelial-mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways.
    Baquero P; Jiménez-Mora E; Santos A; Lasa M; Chiloeches A
    Mol Carcinog; 2016 Nov; 55(11):1639-1654. PubMed ID: 26392228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
    Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
    Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altering FAK-paxillin interactions reduces adhesion, migration and invasion processes.
    Deramaudt TB; Dujardin D; Noulet F; Martin S; Vauchelles R; Takeda K; Rondé P
    PLoS One; 2014; 9(3):e92059. PubMed ID: 24642576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and MEK1/2 inhibition.
    Rose MM; Nassar KW; Sharma V; Schweppe RE
    Med Oncol; 2023 Sep; 40(10):299. PubMed ID: 37713162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Src inhibitors in suppression of papillary thyroid carcinoma growth.
    Henderson YC; Toro-Serra R; Chen Y; Ryu J; Frederick MJ; Zhou G; Gallick GE; Lai SY; Clayman GL
    Head Neck; 2014 Mar; 36(3):375-84. PubMed ID: 23729178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma.
    El Sayed I; Helmy MW; El-Abhar HS
    Life Sci; 2018 Nov; 213():248-257. PubMed ID: 30292831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
    Girotti MR; Pedersen M; Sanchez-Laorden B; Viros A; Turajlic S; Niculescu-Duvaz D; Zambon A; Sinclair J; Hayes A; Gore M; Lorigan P; Springer C; Larkin J; Jorgensen C; Marais R
    Cancer Discov; 2013 Feb; 3(2):158-67. PubMed ID: 23242808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibronectin-stimulated signaling from a focal adhesion kinase-c-Src complex: involvement of the Grb2, p130cas, and Nck adaptor proteins.
    Schlaepfer DD; Broome MA; Hunter T
    Mol Cell Biol; 1997 Mar; 17(3):1702-13. PubMed ID: 9032297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway.
    Cowell LN; Graham JD; Bouton AH; Clarke CL; O'Neill GM
    Oncogene; 2006 Dec; 25(58):7597-607. PubMed ID: 16799644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by alpha1-integrins during colon cancer cell invasion.
    Van Slambrouck S; Grijelmo C; De Wever O; Bruyneel E; Emami S; Gespach C; Steelant WF
    Int J Oncol; 2007 Dec; 31(6):1501-8. PubMed ID: 17982677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.
    Hicks HM; Pozdeyev N; Sams SB; Pugazhenthi U; Bales ES; Hofmann MC; McKenna LR; Schweppe RE
    Mol Cancer Res; 2023 Sep; 21(9):867-880. PubMed ID: 37219859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.
    Caccia D; Miccichè F; Cassinelli G; Mondellini P; Casalini P; Bongarzone I
    Mol Cancer; 2010 Oct; 9():278. PubMed ID: 20955590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies.
    Hicks HM; Nassar VL; Lund J; Rose MM; Schweppe RE
    Cancer Biol Ther; 2024 Dec; 25(1):2332000. PubMed ID: 38521968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between focal adhesion kinase and Crk-associated tyrosine kinase substrate p130Cas.
    Polte TR; Hanks SK
    Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10678-82. PubMed ID: 7479864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Requirement of the p130CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration.
    Zhang XA; He B; Zhou B; Liu L
    J Biol Chem; 2003 Jul; 278(29):27319-28. PubMed ID: 12738793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
    Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
    Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.